MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen of the 2-aminoindane family which is related to MDMA and produces similar subjective effects.
It acts as a selective serotonin and norepinephrine releasing agent (SNRA). The drug shows greatly reduced serotonergic neurotoxicity in comparison to MDMA in animals, although it still shows weak capacity for neurotoxicity with chronic use or in combination with amphetamine.
MDAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It has been encountered as a designer drug and has been used recreationally with reported street names such as "sparkle" and "mindy". In addition to its recreational use, there has been interest in MDAI for potential use in medicine, for instance in drug-assisted psychotherapy.
Safety at a Glance
High Risk- Although no formal studies have been conducted,somewhat habit-forming with a low potential for abuse and is unlikely ...
- This results in users having to administer increasingly large doses to achieve the same effects.
- Toxicity: MDAI and other similar drugs have been widely used in scientific research as they are able to replicate many of the e...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Harmala alkaloid, Peganum harmala, MDMA
- Overdose risk: exact toxic dosage is unknown. Due to its action as a serotonin reuptake inhibitor, overdoses of ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4.8 hrs – 8.7 hrsHow It Feels
The onset of MDAI arrives slowly and gently. An hour or more after ingestion, a soft warmth begins to gather in the chest, spreading outward like a blush of contentment. There is no stimulant push, no surge of energy, no quickening of the pulse. Instead, there is simply a deepening sense of emotional ease, as though a volume knob controlling anxiety and social tension has been quietly turned down. The body relaxes, the shoulders drop, and the face softens into something closer to its resting expression of goodwill.
As the effects develop, MDAI reveals itself as perhaps the purest empathogenic experience available. Emotional openness increases steadily, bringing a warm regard for others that feels natural and unforced. Conversations become more intimate and honest, but without the urgent, confessional quality that serotonin releasers can produce. There is instead a calm willingness to listen, to empathize, and to share that feels like an enhancement of existing emotional capacity rather than an artificial state. Touch is pleasantly heightened, and music gains a gentle emotional richness. But there is no euphoria in any conventional sense, no rush of pleasure, no electrical excitement. The mood is warm, open, and deeply peaceful.
At the peak, two to three hours in, MDAI is notable as much for what is absent as for what is present. There is no stimulation. There is no jaw clenching. There is no significant increase in heart rate or body temperature. The body remains relaxed, almost sleepy. The empathogenic warmth is genuine but gentle, a soft glow rather than a blazing fire. Some users find this subtlety deeply rewarding, a chance to experience emotional openness without the physical cost and neurochemical intensity of MDMA. Others find it insufficient, the emotional content real but the absence of stimulation and euphoria leaving the experience feeling incomplete.
The decline is gentle and unremarkable. The warmth slowly fades over two to three hours, and baseline mood returns without any dramatic transition. The comedown is among the mildest of any empathogenic compound, reflecting the substance's minimal impact on dopamine and its relatively gentle serotonergic action. Sleep comes easily, the next day is normal, and there is little if any neurochemical hangover. MDAI offers a quiet lesson in what empathy feels like when it is separated from stimulation: warm, genuine, and very, very mild.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(17)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(3)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
MDAI has been shown to inhibit the reuptake of serotonin and has a selective affinity for the serotonin receptor. Studies have shown that the brains of animals treated with MDAI have greater extracellular concentrations of monoamine neural transmitters, most significantly serotonin.
For comparison, MDAI is similar in potency with releasing serotonin to MDA, but significantly less potent than MDMA. This is done by inhibiting the reuptake and reabsorption of the neurotransmitters after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate, be reused and cause entactogenic effects.
MDAI and other similar drugs have been widely used in scientific research as they are able to replicate many of the effects of MDMA, but without causing the associated neurotoxicity. No tests have been performed on cardiovascular toxicity.exact toxic dosage is unknown. Due to its action as a serotonin reuptake inhibitor, overdoses of this substance would likely result in serotonin syndrome.
It is strongly recommended that one use harm reduction practices when using this substance.
Although no formal studies have been conducted,somewhat habit-forming with a low potential for abuse and is unlikely to be capable of causing psychological dependence among most users. This is because unlike traditional stimulants, MDAI does not increase concentrations of dopamine. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption).
MDAI presents cross-tolerance with Cross-all entactogens, meaning that after the consumption of MDAI all serotonergic stimulants will have a reduced effect.
MDMA** - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
Cocaine** - This combination may increase strain on the heart to a dangerous degree.
Serotonin syndrome risk
Austria: MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
China: As of October 2015, MDAI is a controlled substance in China.
Denmark: MDAI is illegal in Denmark as of September 2015.
Germany: MDAI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: MDAI is a controlled substance in Japan effective March 30th, 2013.
Switzerland: MDAI is a controlled substance specifically named under Verzeichnis E. It is a controlled substance since December 2011.
Turkey:** MDAI is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: MDAI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
MDMA
2-AI
MDAI (Wikipedia)
MDAI (Erowid Vault)
MDAI (Isomer Design)
Discussion
The Big & Dandy MDAI Thread (Bluelight)
Detection Methods
Standard Drug Panel Inclusion
MDAI (5,6-Methylenedioxy-2-aminoindane) is a methylenedioxy-substituted aminoindane that is not detected on standard 5-panel or 10-panel drug screens. Despite the methylenedioxy group shared with MDMA, the aminoindane core structure reduces cross-reactivity with MDMA/amphetamine immunoassays. Some MDMA-targeted immunoassays may show weak cross-reactivity, but this is inconsistent and should not be relied upon for detection.
Urine Detection
MDAI is detectable in urine for approximately 2 to 4 days. Metabolism involves demethylenation, hydroxylation, and conjugation pathways similar to those seen with MDMA, but the aminoindane core is metabolized differently from amphetamines. The metabolite profile has been partially characterized in forensic literature. Standard immunoassays do not reliably detect MDAI or its metabolites.
Blood and Saliva Detection
Blood concentrations of MDAI are detectable for approximately 12 to 48 hours. Oral fluid testing may detect parent compound for 24 to 48 hours. Neither testing modality routinely includes MDAI in standard or expanded panels.
Hair Follicle Detection
Hair follicle analysis for MDAI is possible using specialized LC-MS/MS methods but is not available through standard commercial laboratories. The methylenedioxy group may improve incorporation into hair compared to unsubstituted aminoindanes, but data on this is limited.
Confirmatory Testing
LC-MS/MS is the preferred confirmatory method for MDAI, offering specificity to distinguish it from MDMA, MDA, and other methylenedioxy compounds. GC-MS can also identify MDAI through its characteristic fragmentation pattern. Reference standards are available from forensic chemistry suppliers.
Reagent Testing
Marquis reagent produces a dark purple to black color with MDAI due to the methylenedioxy group. This reaction is similar to MDMA, making reagent testing alone insufficient to distinguish the two. Mecke reagent produces a dark blue-green color. Simon's reagent is negative (primary amine), which helps distinguish MDAI from MDMA (which is a secondary amine and shows a positive Simon's reaction). This Simon's result is the key differentiator in field testing.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Harmala alkaloid | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| Peganum harmala | Dangerous | Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA |
| MDMA | Unsafe | — |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
MDAI is classified as an empathogen-entactogen, a relatively recently defined class of psychoactive substances characterized by their ability to produce feelings of emotional openness, empathy, and interpersonal closeness.
The term "empathogen" was coined by Ralph Metzner in 1983, while "entactogen" was proposed by David Nichols in 1986 to describe substances that produce a "touching within." MDMA is the prototypical member of this class, originally synthesized by Merck in 1912 but not explored for its psychoactive properties until the 1970s, when Alexander Shulgin resynthesized it and recognized its unique psychological effects.
MDMA was used therapeutically by a small community of psychotherapists before its emergency scheduling in 1985. The subsequent development of MDMA-assisted psychotherapy for PTSD, which has shown remarkable efficacy in clinical trials, represents one of the most significant developments in modern psychopharmacology.
MDAI exists within this broader context of empathogenic pharmacology, sharing key features of the class while possessing its own distinct profile.
Harm Reduction
Although no formal studies have been conducted,somewhat habit-forming with a low potential for abuse and is unlikely to be capable of causing psychological dependence among most users. This is because unlike traditional stimulants, MDAI does not increase concentrations of dopamine. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption).
MDAI presents cross-tolerance with Cross-all entactogens, meaning that after the consumption of MDAI all serotonergic stimulants will have a reduced effect.
MDMA** - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
Cocaine** - This combination may increase strain on the heart to a dangerous degree.
Serotonin syndrome risk
Austria: MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
China: As of October 2015, MDAI is a controlled substance in China.
Denmark: MDAI is illegal in Denmark as of September 2015.
Germany: MDAI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan:
Toxicity & Safety
MDAI and other similar drugs have been widely used in scientific research as they are able to replicate many of the effects of MDMA, but without causing the associated neurotoxicity. No tests have been performed on cardiovascular toxicity.
There is currently no scientific data on the lethal dose of MDAI in humans and the exact toxic dosage is unknown. Due to its action as a serotonin reuptake inhibitor, overdoses of this substance would likely result in serotonin syndrome.
It is strongly recommended that one use harm reduction practices when using this substance.
Dependence and abuse potential
Although no formal studies have been conducted, MDAI can be considered somewhat habit-forming with a low potential for abuse and is unlikely to be capable of causing psychological dependence among most users. This is because unlike traditional stimulants, MDAI does not increase concentrations of dopamine. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of MDAI develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption).
MDAI presents cross-tolerance with all entactogens, meaning that after the consumption of MDAI all serotonergic stimulants will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with MDAI should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
Stimulants - MDAI may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
Tramadol - Tramadol is known to lower the seizure threshold and combinations with stimulants may further increase this risk.
MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
Cocaine - This combination may increase strain on the heart to a dangerous degree.
Serotonin syndrome risk
Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.
MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.
Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
SSRIs - Such as citalopram and sertraline
SNRIs - Such as tramadol and venlafaxine
Addiction Potential
somewhat habit-forming with a low potential for abuse
Overdose Information
exact toxic dosage is unknown. Due to its action as a serotonin reuptake inhibitor, overdoses of this substance would likely result in serotonin syndrome.
It is strongly recommended that one use harm reduction practices when using this substance.
Although no formal studies have been conducted,somewhat habit-forming with a low potential for abuse and is unlikely to be capable of causing psychological dependence among most users. This is because unlike traditional stimulants, MDAI does not increase concentrations of dopamine. If addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption).
MDAI presents cross-tolerance with Cross-all entactogens, meaning that after the consumption of MDAI all serotonergic stimulants will have a reduced effect.
MDMA** - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
Cocaine** - This combination may increase strain on the heart to a dangerous degree.
Serotonin syndrome risk
Austria: MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
China: As of October 2015, MDAI is a controlled substance in China.
Denmark: MDAI is illegal in Denmark as of September 2015.
Germany: MDAI is controlled under the NpSG (*New Psychoacti
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Extreme serotonin syndrome risk; potentially fatal — MAOIs massively potentiate MDMA
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria: MDAI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: MDAI is illegal to possess, produce and sell under Portaria SVS/MS nº 344.
China: As of October 2015, MDAI is a controlled substance in China.
Denmark: MDAI is illegal in Denmark as of September 2015.
Germany: MDAI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: MDAI is a controlled substance in Japan effective March 30th, 2013.
Switzerland: MDAI is a controlled substance specifically named under Verzeichnis E. It is a controlled substance since December 2011.
Turkey:** MDAI is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: MDAI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
2-AI
MDAI (Wikipedia)
MDAI (Erowid Vault)
MDAI (Isomer Design)
Discussion
The Big & Dandy MDAI Thread (Bluelight)
Experience Reports (2)
Tips (5)
Do not combine MDAI with SSRIs, SNRIs, MAOIs, or other serotonergic drugs. Most entactogens are serotonin releasers, and combinations can cause serotonin syndrome which is a potentially fatal medical emergency.
Take regular breaks from physical activity while on MDAI. Entactogens raise body temperature, and combining this with sustained dancing in hot environments is the primary cause of hyperthermia-related emergencies.
Use a milligram scale for MDAI. Entactogens have optimal dose ranges and more is not better. Exceeding the sweet spot increases neurotoxicity and uncomfortable side effects without proportionally increasing positive effects.
If you choose to redose MDAI, take no more than half your initial dose once, about 60-90 minutes in. Repeated redosing primarily extends stimulant effects and comedown without meaningful return of the empathogenic effects.
Stay hydrated but do not overhydrate when using MDAI. Sip water at a steady pace (about 500ml per hour if active). Serotonin releasers cause water retention, and overhydration can lead to fatal hyponatremia.
Further Reading
See Also
References (4)
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- PubChem: MDAI
PubChem compound page for MDAI (CID: 125558)
pubchem - MDAI - TripSit Factsheet
TripSit factsheet for MDAI
tripsit - MDAI - Wikipedia
Wikipedia article on MDAI
wikipedia